Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from tariffs on ...